What you should know:
1. Takeda provided Evox with $44 million upfront.
2. Evox will develop protein replacement and mRNA therapies that will use Oxford University’s exosome delivery platform. The company is currently developing a candidate for Niemann-Pick disease type C and a second undisclosed program, and it could develop up to three more rare disease candidates through the partnership.
3. Takeda will gain rights to any therapies Evox develops, taking them over at the clinical development stage.
More articles on surgery centers:
21 ASCs with coronavirus restrictions or closures
How gastroenterology practices are responding to COVID-19
How COVID-19 has affected Tenet, HCA Healthcare and Surgery Partners’ shares
